G1 Therapeutics, Inc.

NasdaqGS:GTHX Rapport sur les actions

Capitalisation boursière : US$378.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics Dividendes et rachats

Dividende contrôle des critères 0/6

G1 Therapeutics n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

-0.08%

Rendement des rachats

Rendement total pour l'actionnaire-0.08%
Rendement futur des dividendesn/a
Croissance des dividendesn/a
Prochaine date de paiement du dividenden/a
Date ex-dividenden/a
Dividende par actionn/a
Ratio de distributionn/a

Mises à jour récentes sur les dividendes et les rachats

Pas de mise à jour

Recent updates

Article d’analyse • Jul 26

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Those holding G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shares would be relieved that the share price has rebounded 80% in...
Seeking Alpha • Jun 24

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Summary G1 Therapeutics, Inc. faces a setback as a trial for triple-negative breast cancer fails to improve survival, leading to a significant market selloff. The company's main drug, trilaciclib, shows potential for reducing severe neutropenia but fails to meet the primary endpoint in the breast cancer trial. Despite financial challenges and market pessimism, G1 Therapeutics maintains an approved drug with growing sales and potential in niche markets like small cell lung cancer. Read the full article on Seeking Alpha
Article d’analyse • Jun 07

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Key Insights G1 Therapeutics to hold its Annual General Meeting on 13th of June CEO Jack Bailey's total compensation...
Article d’analyse • May 28

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 2.5x G1 Therapeutics, Inc. ( NASDAQ:GTHX ) is definitely a...
Article d’analyse • May 04

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Shareholders of G1 Therapeutics, Inc. ( NASDAQ:GTHX ) will be pleased this week, given that the stock price is up 13...
Seeking Alpha • Mar 22

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Summary G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer, reporting a 29% increase in Cosela's net revenues in Q4 2023. Trilaciclib's further successful development and commercialization are crucial for GTHX's valuation and future revenue streams, and early trials suggest that it is effective. Despite cash burn and dilution concerns, I rate GTHX a speculative "buy" due to its promising revenue growth and product pipeline. Read the full article on Seeking Alpha
Article d’analyse • Feb 27

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shares have retraced a considerable 44% in the last month, reversing a fair...
Article d’analyse • Feb 06

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse • Jan 04

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Despite an already strong run, G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shares have been powering on, with a gain of 61...
Article d’analyse • Jun 08

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

With a price-to-sales (or "P/S") ratio of 2.6x G1 Therapeutics, Inc. ( NASDAQ:GTHX ) may be sending very bullish...
Article d’analyse • May 08

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

Celebrations may be in order for G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shareholders, with the analysts delivering a...
Article d’analyse • Nov 04

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

The analysts covering G1 Therapeutics, Inc. ( NASDAQ:GTHX ) delivered a dose of negativity to shareholders today, by...
Seeking Alpha • Oct 20

G1 Therapeutics: Catalysts Stacking

Summary Though no longer having Boehringer as its launch partner, G1 Therapeutics, Inc. posted good sales traction for Cosela. There are several big data releases going into the year-end and next year that can significantly move the needle on this stock. If data for the first-line label expansion proved positive, Cosela would likely become a blockbuster. G1 Such a study indicates that the greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow in sales and profits far more than industry as a whole. - Phillip Fisher (Warren Buffett's mentor) In biotech investing, you want to pick a company that has multiple catalysts like a data release stacked in close sessions. After all, if one data release flops there would be additional clinical reporting to galvanize the shares price. Despite that its marketing partner Boehringer left, I still like G1 Therapeutics (GTHX) because of the substantial unlocked value in Cosela. Going into yearend and next year, there is a flurry of catalysts that can substantially improve the investment prospects of this company. In this research, I'll feature a fundamental analysis of G1 and share with you my expectation of this intriguing equity. StockCharts Figure 1: G1 Therapeutic Chart About The Company As usual, I'll present a brief corporate overview for new investors. If you're familiar with the firm, I suggest that you skip to the next section. Operating out of the Research Triangle Park, North Carolina, G1 Therapeutics is a commercial-stage company focusing on the innovation and commercialization of next-generation medicines to fulfill the unmet needs in cancers. As the "crown jewel" of this pipeline, Cosela is already FDA-approved for the treatment of chemotherapy-induced myelosuppression in adult patients with metastatic small-cell lung cancer (mSCLC). In expanding its label, G1 is investigating Cosela as monotherapy and in combination with other drugs for various solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Figure 2: G1 Therapeutics chart Mechanism Of Action (MOA) Of Cosela Shifting gears, let us walk through the various fundamental developments pertaining to Cosela/G1. Whenever appropriate, I'd present to you the research format that illustrates the MOA, Disease Context (i.e., DC), and supporting data. That way, you can better appreciate your data forecasting. More importantly, it'll give you more context in "reading the tea leaves" to stay ahead of the market. On this front, you can see that Cosela's MOA is crucial in the treatment of a vast number of cancer indications. Notably, chemotherapy kills both the cancer cells as well as normal cells (including cells of the immune system like the T-cells). But in order for chemotherapy to kill these cells, the cell has to be able to move forward in its "cell cycle." That is to say, those cells have to advance from immature precursors to their matured forms. As a transient CDK46 inhibitor, Cosela "temporarily" halts the cell cycle of key cells needed to combat cancers. Consequently, Cosela can theoretically protect various (i.e., myeloid and lymphoid) cells from damage caused by chemotherapy. With the aforesaid key cells being protected, Cosela ultimately boosts immune system functioning. Notably, this MOA is logical to me, but there is still some "gray area" in my thinking. Simply put, it's not as clear-cut as other MOAs. G1 Figure 3: Cosela mechanism of action Disease Context For Various Cancers As you can imagine, the MOA of Cosela (i.e., boosting immune cells) is very important for the treatment of cancers. After all, tumor cells exert "suppressive effects" on the immune system. As you can appreciate, the MOA of Cosela - in protecting immune/blood cells and strengthening the immune function - "more or less fits" into the cancer Disease Context like puzzle pieces. As such, it explicates and foretells upcoming strong clinical data results. The solid proof in the pudding of Cosela's efficacy is that it is already approved and launched for the treatment of myelosuppression associated with chemotherapy treatment for lung cancer. Upcoming Catalysts In 4Q2022 As catalysts can move the needle on your stock, you want to check up on the vast number of upcoming data reports. Beyond the potential share price appreciation, those catalysts can also ramp up Cosela's sales. Toward year-end, there is an upcoming data release for the Phase 2 trial that assesses Cosela in 24 patients suffering from early-stage triple-negative breast cancer (i.e., TNBC). This study further explores the MOA of Cosela. The study's primary endpoint is the immune-based MOA. That includes Cosela's impact on CD8+ T-cells (i.e., killer T-cells) and regulatory T cells (i.e, T-regs) in the tumor's environment. A key secondary endpoint is the pathological complete response rate (i.e., PCR). That aside, there are two Phase 2 combo investigations poised to release their data soon. The first is a combo study with an antibody-drug conjugate (i.e, ADC) known as Trodelvy for advanced TNBC. Here is where it gets interesting with the second study, i.e., the Phase 2 (PRESERVE 3) trial. Notably, PRESERVE 3 assesses Cosela with chemotherapy and an immune checkpoint inhibitor dubbed Avelumab in 92 patients with bladder cancer. With Enrollment already completed, G1 would release the initial data by yearend. Next year, there are more data releases (i.e., progression-free survival) for PRESERVE 3. Now, PRESERVE 3 is very important because it can position Cosela+Trodelvy to become the first line (i.e, 1L) treatment for bladder cancer. Over the decades, I have noticed that 1L therapeutics have the best chances of becoming blockbusters. G1 Figure 4: PRESERVE 2 trial Commercialization Progress In the latest earnings report, G1 reported $8.7M in Cosela sales. While that isn't much, it's significant for a small company like G1. Had Boehringer still been on board, you can bet that sales would have been much higher. Interestingly, G1 noted in the earnings conference call that Cosela is now approved in China. In connection with the milestone achieved, the China partner (Simcere) will pay G1 $13M as part of the total $156M to be earned. I like that development because G1 can leverage a partner like Simcere who knows the China market. With Simcere, you can expect a stronger revenue ramp-up. Commenting on the recent development, the CEO (Jack Bailey) remarked: The second quarter of 2022 was a period of continued momentum across the G1 organization toward our mission of improving the lives of those impacted with cancer. For the first time, our sales team was in full control of Cosela, interacting with prescribers and driving usage and uptake. Thanks to the quality of these engagements, we experienced nearly 60 percent vial volume growth quarter over quarter - our highest quarterly growth rate since the initial launch period. In addition, our clinical team continued to execute on each of our ongoing clinical trials, including achieving important enrollment milestones in our Phase 3 trial of trilaciclib in patients with colorectal cancer and in our Phase 2 bladder cancer and mechanism of action trials. Financial Assessment Just as you would get an annual physical for your well-being, it's important to check the financial health of your stock. For instance, your health is affected by "blood flow" as your stock's viability is dependent on the "cash flow." With that in mind, you should assess the 2Q2022 earnings report for the period that ended on June 30. As follows, G1 procured $10.5M in total revenues, compared to only $6.6M for the same period a year prior. Of the revenues, Cosela's sales for the respective periods registered at $8.7M and $2.5M. Therefore, product sales increased by 248% year-over-year (YOY).
Seeking Alpha • Sep 29

G1 Therapeutics: Building A Franchise

Summary Today, we put G1 Therapeutics, Inc. in the spotlight. The company's main asset is COSELA, a small-molecule, short-acting, inhibitor of cyclin-dependent kinases 4 and 6. COSELA has been approved for one indication and is in numerous studies targeting other oncology afflictions. So, what's next for G1 Therapeutics as it tries to build out a potential blockbuster franchise? An investment analysis follows in the paragraphs below. "Humility is nothing but artfully disguised arrogance." Gourav Mohanty Today, we take a look at a small developmental concern that has seen a nice rise in its stock over the past couple of months despite a dismal market backdrop. Can the rally in the shares continue? An analysis follows below. Seeking Alpha Company Overview: G1 Therapeutics, Inc. (GTHX) is based in North Carolina. This clinical-stage biopharmaceutical company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Currently, the stock trades just below $13.00 a share and sports an approximate market capitalization of $520 million. September Company Presentation The company's main asset is a drug named trilaciclib which goes by the brand name COSELA. The product is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases 4 and 6. COSELA is used to reduce the risk of blood/bone marrow problems (such as low red/white blood cells and platelets) caused by chemotherapy. It is also tumor-agnostic. September Company Presentation This compound is already FDA approved to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide continue regimen or a topotecan containing regimen for extensive stage small cell lung cancer or ES-SCL in the first quarter of 2021. This is a relatively small indication, and COSELA only did $8.7 million of net product revenue in the second quarter of this year. Vials sold did increase 60% on a year-over-year basis, it should be noted. COSELA was recently approved in China. This entitled G1 Therapeutics to $13 million in the form of a milestone payment and potentially $156 million in additional milestone payouts from its marketing partner Simcere in China as well as double-digit royalties on net product revenues. September Company Presentation However, leadership envisions an entire pipeline based on this asset. Trilaciclib is being evaluated across a range of tumor types and chemotherapy regimens to assess its potential myeloprotection, antitumor efficacy and safety in combination with chemotherapy and other agents. September Company Presentation As you can see above, the company has a couple of registrational studies in progress as well as several Phase 2 trials for various new indications for COSELA. The first registrational trial is targeting metastatic colorectal cancer or mCRC and called PRESERVE 1. This is a global multi-center, randomized placebo-controlled, line extension pivotal 326-person Phase 3 trial of trilaciclib metastatic CRC receiving first-line trilaciclib or placebo administered prior to FOLFOXIRI (a combination of fluorouracil (5-FU), folinic acid, oxaliplatin and irinotecan) and bevacizumab. September Company Presentation The population impacted by mCRC is potentially three times bigger than that SCLC for COSELA. Colorectal cancer is the second-largest cause of cancer death in the United States, with some 150,000 Americans diagnosed with this disease. Most currently receive 5-FU based chemotherapy regimens. September Company Presentation Enrollment for PRESERVE-1 was completed in the second quarter. Initial results from this study, which include those from the primary endpoint in the first quarter of 2023. This trial was pushed back by the invasion of Ukraine. This study was overenrolled to compensate for loss of patient data in Ukraine due to the ongoing conflict. Initial Data from a Pivotal Phase 3 Trial of Trilaciclib in Triple Negative Breast Cancer or mTNBC is due out in the second half of 2023. This 170-person study 'PRESERVE 2' target patients with PD-L1 positive and negative metastatic TNBC receiving first-line gemcitabine and carboplatin. An interim overall survival analysis should be conducted by a data monitoring committee in the second half of 2023. If that data meets the criteria, the trial will stop. If not, it will go onto final analysis. September Company Presentation A Phase II trial for this indication saw robust statistically significant improvements in the most clinically meaningful endpoint of overall survival in patients receiving trilaciclib compared to patients in the control group, with hazard ratios of 0.31 and 0.4 in the two trilaciclib groups. September Company Presentation Initial readouts from three Phase 2 trials for additional indications should be out by the end of this year. September Company Presentation Analyst Commentary & Balance Sheet: Two weeks ago, Wedbush ($25 price target, up from $20 previously), Needham ($32 price target) and H.C. Wainwright ($67 price target) all reissued Buy ratings on the stock. On August 3rd, JPMorgan Chase maintained its Sell rating on the stock with a $14 price target. Insiders were small sellers in the stock through the first half of the year. However, two insiders have taken advantage of the recent pop in the stock to dispose of nearly $1.6 million worth of shares in aggregate over the past six weeks. Just over 10% of the overall float in the shares is currently held short. The company ended the second quarter of this year with just under $145 million in cash and marketable securities on its balance sheet against just north of $75 million in long-term debt. This does not include the $13 million milestone payment from Simcere. The company posted a loss of $39.4 million in the second quarter. Management has guided it believes funding in place is sufficient to fund activities planned into 2024. Verdict: G1 Therapeutics' future looks promising as COSELA or trilaciclib is already approved for one indication with the potential for approval for several larger indications in the years ahead. Readouts from five different trials (Two registrational and three Phase II) should also be out over the next year or so.
Article d’analyse • Aug 04

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Celebrations may be in order for G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 02

G1 Therapeutics Q2 2022 Earnings Preview

G1 Therapeutics (NASDAQ:GTHX) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is -$1.01 (-7.4% Y/Y) and the consensus Revenue Estimate is $8.87M (+34.4% Y/Y). Over the last 2 years, GTHX has beaten EPS estimates 63% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 5 downward. Revenue estimates have seen 3 upward revisions and 3 downward.
Seeking Alpha • Jul 22

G1 Therapeutics: Take Advantage Of The November Data

GTHX will topline the mCRC phase 3 trial in November. This will help expand its label and increase revenues. Although up considerably, GTHX stock is still below its earlier highs. G1 Therapeutics (GTHX) is up 50% since my April write-up. The upward movement started from mid-June, and when I am looking for reasons, I see this - the last patient has been randomized in the Phase 3 clinical trial of trilaciclib for patients with metastatic colorectal cancer (mCRC) receiving chemotherapy (PRESERVE 1). That means, the trial is now fully enrolled. In order to understand why this is important, go through my earlier articles quickly. While trilaciclib is already FDA approved to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer, the stock has been struggling to make money, and mCRC and TNBC are its big indications. The stock was down for a long time after trilaciclib's approval because the drug wasn't making enough money for the company. The principal reason for this was GTHX was not able to find the right marketing partner for its drug, and was thus unable to access the big accounts despite getting reimbursement with a permanent J-code. However, SCLC is a much smaller market than either mCRC or TNBC, and being tumor-agnostic, trilaciclib is eventually going to get approved in these indications. The PRESERVE-1 trial will topline in November this year, while TNBC will be 2-3 years later. The excitement surrounding GTHX is because of mCRC data readout. Here's what PRESERVE-1 looks like: PRESERVE 1 is a global multi-center, randomized placebo-controlled, line extension pivotal Phase 3 trial of trilaciclib in 326 patients with metastatic CRC receiving first line trilaciclib or placebo administered prior to FOLFOXIRI (a combination of fluorouracil (5-FU), folinic acid, oxaliplatin and irinotecan) and bevacizumab. The regimen is given for two consecutive days of every 14-day cycle. Patients are receiving trilaciclib or placebo administered prior to their chemotherapy for a maximum of 12 cycles of induction followed by maintenance therapy. Treatment is administered until disease progression. There are 150,000 US patients with Colorectal cancer, most of whom receive 5-FU based chemotherapy regimen. CRC is the second most common cause of cancer death, representing about 12-14% of all cases. Around 25% of patients present with metastasis at diagnosis, which can eventually go up to 50%. Looking at the numbers, mCRC is about thrice the target market compared to SCLC, which is one reason for recent excitement surrounding trilaciclib. The entire CRC market is estimated to be around $20bn, while SCLC is about a third of that. Most mCRC patients receive a combination of leucovorin, fluorouracil, oxaliplatin, and irinotecan in the first-line setting, often in combination with a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) pathways. While treatment quality has vastly improved over the years, it has also led to increased toxicity, specifically from induced myelosuppression and its resultant problems. This has caused the chemo regimen to be used mainly in younger patients with fewer comorbidities. Trilaciclib is intended to reduce myelosuppression in a lineage-agnostic manner, meaning it is useful whether you have developed neutropenia, anemia or thrombocytopenia. There are no specific phase 2 trials in mCRC available. However: Data from 3 randomized, placebo-controlled, phase 2 clinical trials showed that administering trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression, and reduced the need for supportive care interventions and chemotherapy dose reductions/delays • Additionally, in a randomized phase 2 trial in patients with metastatic triple-negative breast cancer, administering trilaciclib prior to gemcitabine plus carboplatin significantly improved OS compared with chemotherapy alone, potentially through protection and direct activation of immune function

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de GTHX ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de GTHX ont augmenté.

Rendement des dividendes par rapport au marché

G1 Therapeutics Rendement des dividendes par rapport au marché
Comment le rendement du dividende de GTHX se compare-t-il à celui du marché ?
SegmentRendement du dividende
Entreprise (GTHX)n/a
25% du marché (US)1.4%
25% du marché (US)4.2%
Moyenne du secteur (Biotechs)2.4%
Analyste prévisionnel (GTHX) (jusqu'à 3 ans)n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de GTHX par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de GTHX par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de GTHX afin de déterminer si les dividendes versés sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car GTHX n'a signalé aucun versement.

Découvrir des entreprises qui versent des dividendes élevés

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/09/18 15:48
Cours de l'action en fin de journée2024/09/18 00:00
Les revenus2024/06/30
Revenus annuels2023/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

G1 Therapeutics, Inc. est couverte par 8 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Harshita PolishettyB. Riley Securities, Inc.
Dane LeoneBTIG
Charles ButlerD. Boral Capital LLC.